Unravel Biosciences, Inc. announced it raised $500,000 in an initial filing from an offering of $1 Million

Company

Location

About

Diseases are a product of complex interactions among biological layers that we barely understand. Our platform integrates computational drug prediction with on-demand animal models and cutting-edge screening hardware to rapidly connect behavioral and cognitive symptoms to novel therapeutic targets and treatments in a matter of weeks. Unlike other discovery stage companies, Unravel enables unbiased identification of drug targets that span organ systems, including restoring metabolism and reducing inflammation.